Sugi Predict

Sugi Predict / Compounds / SCHEMBL2936976

SCHEMBL2936976

SCHEMBL2936976

CN1CCC(C(=O)Nc2cnccc2CN2CC(=O)N(c3ccc(S(=O)(=O)C(F)(F)F)cc3)C2=O)CC1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 2/20 0.39
▸ IGF1R P08069 2/20 0.36
▸ KMT2A Q03164 3/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ GSK3B P49841 2/20 0.34
▸ CCNE2 O96020 1/20 0.34
▸ CCNE1 P24864 1/20 0.34
▸ CDK2 P24941 1/20 0.34
▸ THRB P10828 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ NAMPT P43490 2/20 0.33
▸ ABL1 P00519 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ DYRK1A Q13627 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ F10 P00742 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2938199 0.91 RXFP1 (0.39) EPHX2IGF1RKMT2AMEN1NPC1
SCHEMBL2933625 0.87 GSK3A (0.42) EPHX2KMT2AMEN1GSK3BABL1
SCHEMBL2936810 0.87 IGF1R (0.39) IGF1RGSK3BTHRBNAMPTABL1
SCHEMBL2941059 0.86 MEN1 (0.39) IGF1RKMT2AMEN1POLBNAMPT
SCHEMBL2939137 0.86 ATM (0.37) IGF1RKMT2AMEN1GSK3BCCNE2
SCHEMBL2938690 0.85 IGF1R (0.53) EPHX2IGF1RKMT2AMEN1GSK3B
SCHEMBL2939826 0.85 IGF1R (0.53) EPHX2IGF1R
SCHEMBL2936854 0.84 IGF1R (0.39) IGF1RGSK3BCCNE2CCNE1CDK2
SCHEMBL2938427 0.83 IGF1R (0.41) IGF1RNAMPTHTT
SCHEMBL2938661 0.83 EPHX2 (0.41) EPHX2IGF1RKMT2AMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 EPHX2 3969/4885IGF1R 1595/4885KMT2A 2567/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA EPHX2 3424/4885IGF1R 962/4885KMT2A 2761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.